Paul Daruwala Biography and Net Worth

Mr. Daruwala has over 25 years of experience in the biopharmaceutical industry and leads multiple facets of Cidara’s operations and strategy, including portfolio and commercial strategy, manufacturing, medical affairs and corporate communications. Prior to joining Cidara in 2014, Mr. Daruwala was at Bristol-Myers Squibb Company, where he served as Vice President of the U.S. Viral Hepatitis Franchise and was responsible for leading the U.S. launch in HCV and running the HBV business for BARACLUDE. Prior to Bristol-Myers Squibb, Mr. Daruwala served as Vice President Commercial & Strategic Management at Vertex Pharmaceuticals, where he helped lead the U.S. launch of INCIVEK for HCV. At the time, INCIVEK became the fastest drug launch to achieve blockbuster status. Mr. Daruwala had previously spent 18 years at Merck in U.S. and global commercial leadership roles in antivirals, antifungals, anti-inflammatory products, business development and evaluation in anti-infectives and oncology, managed markets and sales management. Among these, he led the global commercialization efforts for the first approved echinocandin antifungal drug, caspofungin acetate (CANCIDAS). Paul received his degree in pharmacy from the University of Kentucky.